-

Shareholder Alert: Robbins LLP Announces STAAR Surgical Company (STAA) Sued for Misleading Shareholders

SAN DIEGO & LAKE FOREST, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of STAAR Surgical Company (NASDAQ: STAA) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 26, 2020 and August 10, 2020. STAAR Surgical designs, develops, manufactures, markets, and sells implantable lenses for the eye and delivery systems to deliver the lenses into the eye.

If you suffered a loss due to STAAR Surgical's misconduct, click here.

STAAR Surgical Company (STAA) Accused of Misleading Shareholders

According to the complaint, STAAR Surgical reported positive financial results for its fourth quarter and fiscal year ended January 3, 2020. STAAR Surgical reiterated its positive financial results in its COVID-19 business update and first quarter 2020 earnings report, each time, noting the Company's strong relationship with its distributor in China. However, on August 5, 2020, STAAR Surgical reported decreased net sales and a net loss of $0.03 per share for second quarter 2020. On this news, the Company's share price fell approximately 10%, to close at $55.86 on August 6, 2020. Then, on August 2020, J Capital Research released a scathing report asserting that the Company may have "overstated sales in China by at least one-third, or $21.6 million" meaning "all of the company's $14 million in 2019 profit is fake." The report noted, "without the fraud that we believe pervades the China business, STAAR is losing money." On this news, the Company's share price fell approximately 6.2%, to close at $48.25 per share on August 11, 2020. The stock continues to decline.

If you purchased STAAR Surgical Company (STAA) shares between February 26, 2020, and August 10, 2020, you have until October 19, 2020, to ask the court to appoint you lead plaintiff for the class.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against STAAR Surgical settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003

Robbins LLP

NASDAQ:STAA

Release Versions
$Cashtags

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the SES AI Corporation Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired SES AI Corporation (NYSE: SES) securities between January 29, 2025 and March 4, 2026. SES claims to be a "leading developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (“Li-Metal”) and Lithium-ion (“Li-ion”) rechargeable battery technologies and battery materials for Energy Storage Systems (“ESS”), Urban Air Mobility (“UAM”)...

Investor Notice: Robbins LLP Informs Investors of the Regencell Bioscience Holdings Limited Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

Investor Notice: Robbins LLP Informs Investors of the Globant S.A. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Globant S.A. (NYSE: GLOB) common stock between February 15, 2024 and August 14, 2025. Globant is a Luxembourg-incorporated international technology company that provides digital consulting and related services. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LL...
Back to Newsroom